Vance Terry
Known title: DirectorCIK: 0001572282
Associated companies
Transaction History
| ENTA | ▼ Sell | Open Market | 15,295 | $139K | 12/13/2023 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 5,800 | $81K | 3/16/2023 | View on chart |
| ENTA | ▼ Sell | Open Market | 15,295 | $139K | 12/13/2023 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 5,800 | $81K | 3/16/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.